Ipsos explores challenges and opportunities in the development of emerging therapeutic modalities aimed at addressing solid tumors as well as prominent topics in the field. These include: the dominance of small molecules as a time-tested and well-established modality that nonetheless continues to lead in FDA approval numbers each year; the potential of cancer vaccines to break through to the forefront owing to the opportunities created by mRNA-based neoantigens; and the journey of cell therapies as they start to penetrate solid tumor applications.

In this white paper, underpinned by oncology expert views gathered through Ipsos’ recent surveys, we reveal 5 key themes in oncology and how past lessons inform innovations of today.

Contacts: Joel Sandler, PhD and Eric Blouin.